A filler complication becomes an emergency at the point where perfusion may be compromised. Managing vascular occlusion after fillers is therefore not a matter of waiting to see whether discomfort settles, nor of relying on a single visible sign. It demands rapid clinical judgement, a rehearsed response, clear communication and an unambiguous commitment to patient safety over aesthetic convenience.
Vascular compromise is uncommon, but its consequences can be profound. Cutaneous necrosis, scarring and, in the most serious cases, visual disturbance or blindness are preventable harms only when warning signs are recognised early and escalation is immediate. Every clinician who injects dermal filler should regard complications training, emergency equipment and referral pathways as integral to competent practice.
Recognising vascular occlusion early
The presentation is variable. Severe or escalating pain during injection is concerning, particularly when it is disproportionate to the procedure. However, pain is not a dependable sole marker. Local anaesthetic, patient anxiety, previous treatment and individual variation can obscure the clinical picture.
Blanching, livedo reticularis, delayed capillary refill, dusky discolouration and coolness of the skin require immediate attention. Changes may appear at the injection site or along the anatomical territory supplied by a compromised vessel. A mottled, violaceous pattern can evolve over minutes or hours, which is why observation does not end when the needle or cannula is withdrawn.
Visual symptoms are a separate emergency. Blurred vision, visual field loss, ocular pain, ptosis, ophthalmoplegia, nausea or severe headache following filler treatment require urgent emergency transfer and immediate ophthalmological assessment. No clinic-based intervention should delay that transfer. The clinician must communicate clearly that an intravascular event is suspected and provide the exact product, volume, sites and time of injection.
Patients should be told before treatment that they must contact the clinic without delay if they experience increasing pain, unusual colour change, cold skin, blistering or any visual symptom. Informed consent is not simply a signed form. It is an active safety process that gives the patient a clear route back to medical care.
The first response: stop, assess and escalate
When vascular occlusion is suspected, stop injecting immediately. Do not attempt to complete the planned treatment or disguise the emerging signs with further product. Record the time, assess pain and skin colour, check capillary refill and take clinical photographs where appropriate. These observations provide a baseline for the evolving response and for any colleague receiving the case.
The next steps depend on the product used, the anatomical area, the nature of the symptoms and the clinician's competence. If hyaluronic acid filler is implicated, prompt treatment with hyaluronidase according to current recognised complications guidance is central to management. It should be administered by a suitably trained prescriber or practitioner operating within an established clinical protocol, with an understanding of allergy risk, dosing principles and repeat assessment.
Hyaluronidase should not be regarded as a symbolic rescue injection. In suspected hyaluronic acid-related vascular compromise, treatment must be purposeful, adequately distributed across the affected vascular territory and reassessed frequently. Persistent signs of impaired perfusion warrant further intervention and urgent specialist advice. Protocols vary in their recommended dose and technique, reflecting the limited nature of high-level evidence in a rare complication. This is precisely why clinics should work from an up-to-date, practised protocol rather than from memory or social media fragments.
Gentle measures intended to support perfusion may be considered within established guidance, but they must never substitute for urgent definitive management or referral. Equally, aggressive massage is not benign. It can increase pain, create further trauma and distract from the need for rapid escalation. The objective is restoration of blood flow, not simply visible improvement at the skin surface.
Why product history changes the plan
A decisive first question is whether the injected material was hyaluronic acid. Hyaluronidase can degrade hyaluronic acid fillers, but it does not reverse vascular compromise caused by calcium hydroxylapatite, poly-L-lactic acid, polymethylmethacrylate or permanent fillers. In these circumstances, urgent specialist assessment becomes even more significant.
The product record must therefore be complete and immediately accessible. Brand, batch number, amount used, injection plane, device, anatomical sites, use of vasoconstrictor-containing anaesthetic and treatment times are not administrative details. They are clinically relevant information in an emergency and essential to continuity of care.
Previous filler in the area also matters. Tissue planes may be altered, and delayed reactions or previous products may complicate interpretation. A patient who reports that they have had "a little filler" elsewhere may have received a different product, at a different depth, months or years earlier. Careful history-taking remains a safety intervention.
Anatomy remains the best prevention
Managing vascular occlusion after fillers begins long before an adverse event. A detailed understanding of three-dimensional facial anatomy, known danger zones and an individual's vascular variation is fundamental. The glabella, nasal region, forehead, temples and nasolabial area warrant particular respect, but no site is entirely without risk.
Technique lowers risk but does not eliminate it. Slow injection, small aliquots, minimal pressure, constant observation of the skin and careful product selection all contribute to safer practice. Aspiration may have a role in an individual clinician's risk-reduction strategy, yet it cannot be treated as proof that a vessel is absent. A negative aspiration result does not guarantee safety, particularly given the variables of needle position, vessel collapse, filler rheology and device design.
Cannulas may reduce the likelihood of vascular penetration in some contexts, but they do not make a treatment risk-free. They can enter vessels, and their use can create false reassurance when anatomical knowledge or force control is inadequate. The mature approach is not to seek a single protective technique. It is to combine sound anatomy, conservative planning, appropriate equipment and the willingness to stop.
Building a clinic that can respond
A complication protocol is only useful if the whole team can enact it under pressure. Reception staff should know that reports of severe post-treatment pain, colour change or visual symptoms are prioritised immediately. Clinicians should know who is responsible for assessment, where emergency medicines and equipment are stored, and which senior colleague, emergency department, ophthalmology service or plastic surgery service can be contacted.
Regular simulation is valuable. A short team exercise can expose practical failings that a written policy will miss: an expired medicine, uncertainty about who can prescribe, inaccessible patient records or a lack of transport arrangements for transfer. These are not minor operational issues. In a time-critical event, they influence outcome.
Documentation should be factual, contemporaneous and complete. Record the patient's symptoms, objective findings, product details, advice given, interventions performed, discussions with specialists and all follow-up contacts. Clinical photographs, taken respectfully and with appropriate consent, can assist in monitoring progression. Patients should receive clear written instructions, including how to access urgent review outside normal clinic hours.
Follow-up protects tissue and trust
The first intervention is not the end of care. Patients with suspected vascular compromise require close review until perfusion is stable and the risk of tissue injury has passed. Deterioration, blistering, ulceration, increasing pain or systemic symptoms require renewed assessment and specialist involvement. Wound care, infection surveillance, scar prevention and psychological support may all become relevant depending on the extent of injury.
Communication during this period should be calm, candid and compassionate. Avoid false reassurance, but do not communicate in a way that creates panic. Explain what is known, what remains uncertain, what action is being taken and when the patient will next be reviewed. Patients often judge clinical leadership not by the absence of difficulty, but by the competence and humanity demonstrated when difficulty arises.
For aesthetic medicine to retain public confidence, complications management must be taught with the same seriousness as treatment technique. The standard is not merely to create a pleasing immediate result. It is to practise medicine responsibly, protect long-term tissue health and be prepared to act decisively when a rare complication tests the entire clinical system.